{"brief_title": "Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia", "brief_summary": "The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.", "condition": ["Schizophrenia"], "intervention_type": ["Drug"], "intervention_name": ["Quetiapine Fumarate"], "criteria": "Inclusion Criteria: - Patient is able to provide written informed consent before beginning any study related procedures - Patient has a documented clinical diagnosis of schizophrenia - Patient is able to understand and comply with the requirements of the study, as judged by a study investigator Exclusion Criteria: - Patients with a history of non-compliance as judged by the study investigator - Patients with a known lack of response to previous treatment with quetiapine - Patients who have participated in another drug study within 4 weeks prior to enrollment into this study - Patients who have previously participated in this study or study D1444C00132", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "Schizophrenic disorder", "mesh_term": ["Schizophrenia", "Quetiapine Fumarate"], "id": "NCT00085891"}